产品名称

N-[[2-[[(4-氰基苯)胺]甲基]-1甲基-1H-5-苯并咪唑]羰基]3-氨基苯酰基]N-2-吡啶基-b-丙氨酸乙酯

CAS NO

211915-84-3

中文别名

N-[[2-[[(4-氰基苯)胺]甲基]-1甲基-1H-5-苯并咪唑]羰基]3-氨基苯酰基]N-2-吡啶基-b-丙氨酸乙酯

英文名称

ethyl 3-[[2-[(4-cyanoanilino)methyl]-1-methylbenzimidazole-5-carbonyl]-pyridin-2-ylamino]propanoate

英文别名

1-methyl-2-<2-methylthio-2-(4-methyl-1-piperazino)vinyl>-quinolinium iodide;1-methyl-2-[N-(4-cyanophenyl)-aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-(2-pyridyl)-N-(2-ethoxycarbonylethyl)-amide;3-({2-[(4-cyano-phenylamino)methyl]-1-methyl-1H-benzoimidazole-5-carbonyl}pyridin-2-ylamino)propionic acid ethyl ester;ethyl 3-(2-((4-cyanophenylamino)methyl)-1-methyl-N-(pyridin-2-yl)-1H-benzo[d]imidazole-5-carboxamido)propanoate;ethyl 3-([2-[(4-cyanophenylamino)methyl]-1-methyl-1H-benzimidazole-5-carbonyl]pyridin-2-ylamino)propionate;3-[[2-[(4-cyanophenylamino)methyl]-1-methyl-1H-benzimidazole-5-carbonyl]pyridin-2-yl-amino]propionate;1-methyl-2-[N-(4-cyanophenyl)aminomethyl]benzimidazole-5-yl-carboxylic acid-N-(2-pyridyl)-N-(2-ethoxycarbonylethyl)amide;查看更多英文别名收起

分子式

 

分子量

482.53400

EINECS

1592732-453-0

熔点

沸点

756.382ºC at 760 mmHg

毒性

达比加群中间体 达比加群酯是前沿的新一代口服抗凝药物直接凝血酶抑制剂(DTIs)，用于预防非瓣膜性房颤患者的卒中和全身性栓塞。达比加群酯可提供有效的、可预测的、稳定的抗凝效果，同时较少发生药物相互作用，无药物食物相互作用，无需常规进行凝血功能监测或剂量调整。 达比加群 Dabigatran N-(4-Cyanophenyl)glycine N-(4-氰基苯基)甘氨酸 42288-26-6 3-[3-aMino-4-(MethylaMinobenzoyl)-pyridin-2-ylaMni]propionic acid ethyl ester 3-[(3-氨基-4-甲基氨基苯甲酰)吡啶-2-基氨基]丙酸乙酯 212322-56-0 Hexyl chloroformate 氯甲酸正己酯 6092-54-2 3-[[[2-[[(4-Cyanophenyl)amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl]pyridin-2-ylamino]propionic acid ethyl ester 3-[[[2-[[(4-氰基苯基)氨基]甲基]-1-甲基-1H-苯并咪唑-5-基]羰基]吡啶-2-基氨基]丙酸乙酯 211915-84-3 4-(METHYLAMINO)-3-NITROBENZOIC ACID 4-甲氨基-3-硝基苯甲酸 41263-74-5 Ethyl 3-(pyridin-2-ylamino)propanoate 3-(吡啶-2-基氨基)丙酸乙酯 103041-38-9